Table 2

Characteristics of primary Sjögren's syndrome patients

Primary Sjögren's patients (N=395)
Age (years)57.5(46–66)55.4±13.7
Sex (female)378 (95.7%)
Disease duration (years)6 (2–12)7.6±6.4
Ocular symptoms358 (90.9%)
Oral symptoms368 (93.4%)
Objective ocular involvement313 (79.48%)
Objective oral involvement286 (72.6%)
Positive salivary gland biopsy250/259 (96.5%)
Autoantibodies to antiSSA or antiSSB317 (80.4%)
 Anti-SSA313 (79.44%)
 Anti-SSB202 (51.3%)
Present or past systemic involvement251 (63.7%)
 Cutaneous109 (29.2%)
 Articular140 (37.4%)
 Muscular20 (5.0%)
 Pulmonary58 (14.5%)
 Central nervous system14 (3.7%)
 Peripheral nervous system41 (10.4%)
 B-cell proliferative disorder19 (4.8%)
 Present systemic involvement145 (36.8%)
Present or past salivary gland swelling202 (51.3%)
 Present salivary gland swelling87 (22.9%)
Current treatment
 Corticosteroids96 (24.3%)
 Hydroxychloroquine115 (29.1%)
 Azathioprine13 (3.3%)
 Methotrexate16 (4.1%)
 Rituximab12 (3.0%)
 Other immunosuppressant22 (5.6%)
 Pilocarpine44 (11.1%)
 Lacrymal substitute305 (77.2%)
 Saliva substitute132 (33.4%)
Disease activity indexes
 Physician outcome measures
  ESSDAI6 (2–12)8.6±8.7
  SCAI7 (5–10)8.1±5.5
  SSDAI1 (0–2)1.3±1.0
  PhGA3 (2–5)2.2±3.0
 Patient-centred measures
  ESSPRI6 (4.3–7.3)5.8±2.3
  SSI4.9 (3.2–6.6)4.8±2.3
  PROFAD4.2 (2.8–5.8)4.4±2.2
  PGA7 (4–8)6.1±2.6
  • Results are expressed as median (Inter-quartile range) and mean±SD or number (%).

  • ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; EULAR, European League Against Rheumatism; PGA, patient global assessment; PROFAD, Profile of Fatigue and Discomfort; SCAI, Sjögren's Systemic Clinical Activity Index; SSA, Sjogren's syndrome A; SSB, Sjogren's syndrome B; SSI, Sicca Symptoms Inventory.